Company intelligence / Profile preview
mbiomics
Munich, Bavaria, Germanymbiomics.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
mbiomics has achieved technological proof-of-concept for its proprietary analytics platform, enabling the rational selection and design of complex live bacterial therapeutics. The company is building a pipeline targeting severe and chronic diseases by restoring healthy gut microbiota. No clinical results have been published yet; the focus remains on preclinical development and candidate identification.
- Therapeutic areas
- GastroenterologyImmunologyOncology
- Modalities
- Live biotherapeutic product therapyMicrobial therapyBiologic (as umbrella for live microbial consortia)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025. Strategic partnerships anticipated as part of growth strategy post-Series A funding.
Beyond the preview
Go deeper on mbiomics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mbiomics.